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Machado–Joseph disease (MJD) is a neurodegenerative disorder, caused by the expansion of the (CAG)n tract in the MJD gene. This
encodes the protein ataxin-3, of unknown function. The mouse Mjd gene has a structure similar to that of its human counterpart and it also
contains a TATA-less promoter. Its 5V flanking region contains conserved putative binding regions for transcription factors Sp1, USF, Arnt,
Max, E47, and MyoD. Upon differentiation of P19 cells, the Mjd gene promoter is preferentially activated in endodermal and mesodermal
derivatives, including cardiac and skeletal myocytes; and less so in neuronal precursors. Mouse ataxin-3 is ubiquitously expressed during
embryonic development and in the adult, with strong expression in regions of the CNS affected in MJD. It is particularly abundant in all types
of muscle and in ciliated epithelial cells, suggesting that it may be associated with the cytoskeleton and may have an important function in
cell structure and/or motility.
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Machado–Joseph disease (MJD), also known as spino- The MJD causative gene was mapped to chromosomecerebellar ataxia type 3 (SCA3), is a neurodegenerative
disorder of late onset and the most common dominant
spinocerebellar ataxia worldwide (30% among all forms)
[1]. Patients present with cerebellar ataxia and progressive
external ophthalmoplegia, associated in a variable degree
with pyramidal signs, extrapyramidal signs (dystonia or
rigidity), amyotrophy, and peripheral neuropathy [2]. Patho-
logically, MJD is characterized by neuronal loss in the
spinocerebellar, dentate, pontine, and vestibular nuclei, the
substantia nigra, the locus coeruleus, the palidoluysian
complex, the motor cranial nerve and medulla anterior horn
nuclei, and the dorsal root ganglia [2–4].0888-7543/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygeno.2004.02.012
$ Supplementary data for this article may be found on ScienceDirect.
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E-mail address: pmaciel@ecsaude.uminho.pt (P. Maciel).14q32.1 in 1993 [5] and cloned in 1994 [6], but its structure
has only recently been elucidated [7]. Alternative splicing
of MJD results in the production of different isoforms of
ataxin-3 [8], which are expressed in various tissues and have
been detected both in the nucleus and in the cytoplasm [7,9–
11]. MJD is one of the CAG repeat/polyglutamine disorders,
which includes Huntington disease (HD), spinal and bulbar
muscular atrophy, dentatorubropallidoluysian atrophy
(DRPLA), and other spinocerebellar ataxias, such as
SCA1, 2, 6, 7, 12, and 17. Each is characterized by selective
neuronal cell death in specific regions of the brain, and their
causative genes do not show homology with each other,
except for the polyglutamine segment itself. The minimal
poly(Q) length to cause disease is variable among these
disorders. The CAG repeat tract in MJD contains 10–51
triplets in healthy individuals and 55–87 in patients [12,13].
Mutant ataxin-3, like other pathogenic proteins carrying
expanded poly(Q) stretches, appears to undergo a confor-
mational change and aggregate in cells forming inclusion
Fig. 1. Multiple sequence analysis of mouse and rat ataxin-3 homologues and human ataxin-3 variants (CLUSTALW). Aligned residues that are identical or
similar are shaded with a black or gray background, respectively.
M. do Carmo Costa et al. / Genomics 84 (2004) 361–373362bodies [12]. Ubiquitinated neuronal intranuclear inclusions
(NIIs) have been observed in the brains of patients [14],
cultured cells [15], and transgenic mouse models [16,17].Table 1
Exon– intron boundaries of the mouse Mjd gene
Exon/intron Length (bp) A
Exon Intron
Exon 1 67
Intron 1 10098
Exon 2 165 g
Intron 2 226
Exon 3 45 a
Intron 3 2084
Exon 4 86 c
Intron 4 367
Exon 5 67 tt
Intron 5 3198
Exon 6 88 tt
Intron 6 4648
Exon 7 133 c
Intron 7 3192
Exon 8 167 tg
Intron 8 1183
Exon 9 97 tt
Intron 9 6386
Exon 10 98 a
Intron 10 3279
Exon 11 97 tcThe observation that NIIs sequestrate transcriptional activa-
tors/coactivators suggests that an interference with gene
transcription might be underlying the polyglutamine patho-cceptor site Donor site
CCACGAGAAA/gtgagtgtgg
aaacactag/CAAGAAGGCT ATTTTTACAG/gtactgattt
attgaacag/CAGCCTTCTG CTCTATTCAA/gtaagtagtc
ttttgacag/GTTATAAGCA TTGATCCTAT/gtaagatttt
tcttctag/AAACGAAAGA AGGCAAGCAG/gtaatatatc
tttcctag/TGGTTTAACT CAGCAAGAAG/gtaaataaga
tctttttag/GTTATTCTAT AAGAGCAGAG/gtaaaactac
ttgtttag/TGCCCTCAAA AGTATGCAAG/gtttggacat
gtttttag/GTAGTTCCAG ACTTTGAAAA/gtaaagtagt
atgtttcag/GCAACAGCAG AGCGACCAAG/gtttgctttc
tttcccag/GAGGCGACGC
Fig. 3. Binding of MyoD to the Mjd gene promoter. EMSAs were
performed with 2.5 (lane 2), 5 (lane 3), or 15 Ag (lane 4) of purified
recombinant MyoD incubated with the 928 bp fragment of the promoter.
For the competition assay 2.5 Ag of purified recombinant MyoD was
incubated with 2 (lane 6) or 4 Ag (lane 7) of competitor double-stranded
oligonucleotides followed by the addition of the928 bp fragment. Lanes 1
and 5 correspond to the 928 bp fragment of the promoter.
M. do Carmo Costa et al. / Genomics 84 (2004) 361–373 363genic mechanism [18]. It is not clear, however, if these NIIs
are the cause or a consequence of the pathogenic mecha-
nism. The potential conformational change and protein
misfolding may be of importance to pathogenesis, since
increased expression of chaperones can diminish the
poly(Q) toxicity [19,20], while inhibition of the proteasome
pathway enhances cell death [21,22]. Another hypothesis
for the mechanism of neurodegeneration is the possibility of
amyloid formation, as in Alzheimer disease and other
neurodegenerative disorders, but with a different subcellular
location [23]. Infrared spectroscopy measurements have
shown that ataxin-3, containing an expanded poly(Q) tract,
also forms fibrils in vitro presenting a higher content of hFig. 2. Nucleotide sequence of the 5V flanking region of the mouse Mjd
gene. The translation start site is numbered as +1. Uppercase letters
represent exon sequences and untranscribed sequences are represented by
lowercase letters. The coding region of the first exon is shown as codon
triplets. For the detection of promoter activity, an arrowhead indicates the
start point of each construct. Consensus binding sequences of the conserved
transcription factor binding sites are boxed; other potential transcription
factor binding sites are indicated by a line.sheets [24]. There is evidence that polyglutamine aggregates
exhibit most of the features of amyloid [25].
The first transgenic mouse models of MJD were gener-
ated with truncated and full-length human MJD1a cDNAs
(containing 79 CAGs) under the control of the L7 promoter,
which specifically directs their expression in Purkinje cells
[16]. Recently, YAC transgenic mouse models for MJD
were also generated [17]. These mice, carrying the full-Fig. 4. Functional analysis of the mouseMjd gene promoter. (A) A series of
constructs containing different sizes of the 5V flanking region of the Mjd
gene was transfected into P19 cells. CAT activity is represented in arbitrary
units, normalized for h-galactosidase activity and for total protein amount.
(B) Activation of the mouse Mjd promoter during RA- or DMSO-induced
differentiation of P19 cells. Undifferentiated P19 were incubated with
medium or with DMSO- or RA-supplemented medium, on bacterial-grade
petri dishes, for 3 days, then dissociated, transfected with p-237MjdCAT
and p-1173MjdCAT constructs, and further grown on tissue culture plates.
Cells were harvested at day 3 after replating (day 6 after induction of
differentiation). Data are expressed as the fold increase in CAT activity
compared with transfections using empty CAT plasmid, pCAT3-Basic.
The results are the averages of three independent transfections F SEM
(error bars).
M. do Carmo Costa et al. / Genomics 84 (2004) 361–373364length human MJD gene with expanded CAG repeats and
its own regulatory elements, showed a mild and slowly
progressive cerebellar deficit, cell loss in the dentate and
pontine nuclei, as well as in other regions of the cerebellum,
and peripheral nerve demyelination.
The function of ataxin-3 remains unknown. Recent
studies suggest that ataxin-3 protein interacts with DNA-
repair proteins HHR23A and HHR23B [26] and with the
major histone acetyltransferases CBP, p300, and PCAF [27].
A recent computational structure-based sequence alignment
study revealed that ataxin-3 has homology to ENTH and
VHS domain proteins, which are involved in membrane
trafficking and regulatory adaptor functions [28].
Several protein sequences highly homologous to human
ataxin-3 have been described in rat [29] and chicken [30]
and found in databases for mouse, Fugu, Drosophila,
Caenorhabditis elegans, and Arabidopsis thaliana [28],
suggesting that this protein is highly conserved throughout
evolution and has functional relevance. To gain insight into
the function of ataxin-3, we isolated and characterized the
mouse Mjd gene. We cloned mouse Mjd, determined its
genomic structure, characterized (spatially and functionally)
the promoter region using the P19 cell model, and analyzed
the expression pattern of mouse ataxin-3 during embryonic
development and in the adult, using immunohistochemistry
and immunoblotting techniques. Our results indicate that
mouse ataxin-3 is ubiquitously expressed and is develop-
mentally regulated, with high expression in muscle and
ciliated epithelial cells, as well as in regions of the central
nervous system (CNS) affected in MJD.Fig. 5. Mouse ataxin-3 expression in wild-type C57Bl/6 mouse tissues. Protein e
reveals immunoreactive bands of 42 and 160 kDa present in all tissues analyzed. H
38 kDa, while skeletal muscle presented an additional band of 40 kDa.Results
Cloning of full-length cDNA and analysis of mouse Mjd
gene organization
Using one of the cDNA sequences of human MJD
(pMJD1a), we searched for homologous sequences in
GenBank and found one mouse cDNA (Accession No.
AK008675) with 1097 bp. A full-length mouse cDNA
clone with 1100 bp (pMjd1) was obtained by RT-PCR from
cerebral cortex total RNA and verified by sequencing.
Analysis of the nucleotide sequence revealed 88, 84, 81,
80, and 68% identity with the human MJD1-1, MJD5-1,
MJD1a, MJD2-1, and H2 cDNA sequences, respectively,
and 92% identity with the rat homologue cDNA. The pMjd1
cDNA contains a coding region of 1065 bp, predicted to
encode a 355-amino-acid protein—mouse ataxin-3.
A multiple sequence alignment, using CLUSTAL W, of
mouse ataxin-3 with rat ataxin-3 and human ataxin-3-v1,
ataxin-3-v2, ataxin-3-v3 [28], and ataxin-3-v4 (see Materi-
als and methods) showed a 94, 86, 80, 82, and 83% identity,
respectively, at the amino acid level (Fig. 1). This indicates
that the obtained sequence is in fact the mouse homologue
to human ataxin-3.
A probe of 400 bp (nucleotides 1 to 400 of the cDNA),
obtained by PCR, was used to screen a BACMouse II library.
One positive BAC clone was identified and sequenced.
Comparisons of the mouse cDNA clone sequence with the
BAC clone sequence enabled us to determine the exon/intron
structure of the mouse Mjd gene (Table 1). This gene ofxtracts were resolved on 10% SDS–polyacrylamide gels. Immunoblotting
eart, skeletal muscle, and testis presented another, lower molecular mass of
M. do Carmo Costa et al. / Genapproximately 36 kb, localized on chromosome 12, is very
similar to its human counterpart, in both number and sizes of
exons and introns. Mjd is composed of 11 exons and 10
introns, carrying a (CAG)6 repeat on exon 10 (Table 1). Thus,
the genomic structure of mouseMjd is highly homologous to
that of humanMJD,which is localized on chromosome 12, in
a region syntenic to the human chromosome 14.Fig. 6. Mouse ataxin-3 immunoreactivity in adult mouse tissues. Bright-field micr
(C) cardiac muscle, (D) smooth muscle, (E) pancreas, (F) control for staining, with
liver. (A–D) High immunoreactivity was found in all types of muscles analyzed. (
the islets of Langerhans, though it was also present in the exocrine component. (G)
the testis, the protein was also widely distributed, both within and outside th
spermatocytes, spermatids, and spermatozoa and appeared to be absent on Sertoli c
In the liver, mouse ataxin-3 immunoreactivity was widely distributed throughout
intense perimembrane staining, and (K) high magnification of spermatozoa. The ar
ataxin-3 immunoreactivity; in (D), the smooth muscle layer in the tunica propria of
lower right corner is equivalent to 50 Am. h, hepatocyte; il, islet of Langerhans; l
spermatocytes; st, spermatids; sz, spermatozoa; v, venule; wp, white pulp.Sequence analysis of the 5V flanking region
Analysis of the 5V flanking region ofMjd revealed that its
promoter consists of a sequence lacking TATA boxes or
CCAAT boxes, similar to the human counterpart (Fig. 2).
The G+C-rich region extends from 307 to 8 bp (GC
content, 68%). Analysis of the 1173-bp region upstream of
omics 84 (2004) 361–373 365ographs of (A) transversal and (B) longitudinal sections of skeletal muscle,
out the primary antibody, in pancreas section, (G) spleen, (H) testis, and (I)
E) In the pancreas, staining was ubiquitous and could be clearly observed in
In the spleen, labeling was found in both the white and the red pulp. (H) In
e seminiferous tubules; in the tubules, it was found on spermatogonia,
ells; high reactivity was also found in the surrounding tunica propria (D). (I)
the section. (J) High magnification of two hepatocytes evidencing the more
rows point to, in (A, B), a nucleus of muscular cell, showing no anti-mouse
the testis; and in (K), the flagellum of a spermatozoon. The black bar on the
c, Leydig cells; pa, pancreatic acinar cells; rp, red pulp; sc, Sertoli cell; sp,
Fig. 7.
Fig. 8.
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vation of putative transcription factor binding regions using
the TRES/TRANSFAC program revealed the presence of
putative Sp1, upstream stimulatory factor (USF), aryl hydro-
carbon receptor nuclear translocator (Arnt), Myc-associated
factor X (Max), E47 and MyoD regulatory element binding
sites, and also GC box elements in the gene promoters of both
species (see supplementary data). Potential transcription
factor binding sites for GATA-4, Nkx-2.5, myogenin, myo-
cyte-specific enhancer factor-2 (MEF-2), c-Myb, activating
enhancer-binding protein-2a (AP-2a), retinoic acid receptor-
g/retinoid X receptor-h (RAR-g/RXR-h), N-Oct-3, SRY-
related HMG-box-5 (Sox-5), glucocorticoid receptor (GR),
activating protein-1 (AP1), and Myc-associated zinc-finger
protein (MAZ) were also found in the 5V flanking region of
mouseMjd (see supplementary data). These data suggest that
the Mjd gene may be developmentally regulated.
Binding of MyoD to the Mjd promoter
To confirm the binding of the transcription factor MyoD,
whose target region is conserved in mouse and human, we
expressed and purified a recombinant mouse MyoD-His tag
protein and analyzed its binding to the 928 bp fragment of
the 5V flanking region of the Mjd gene by electrophoretic
mobility-shift assay (EMSA). We analyzed the binding of
various quantities of the recombinant protein (2.5, 5, and 15
Ag) to the DNA and verified that the binding, as revealed by
gel retardation assay, increased proportionally with the
amount of protein added (Fig. 3). To verify that the binding
of the recombinant protein to the 928 bp fragment was
specific, we performed a competition assay using two
different quantities of oligonucleotides corresponding to
the MyoD binding region of the Mjd gene promoter (local-
ized at position 888 bp) and verified that in the presence of
these oligonucleotides the binding of the recombinant pro-
tein to the promoter fragment decreased proportionally to
the amount of competing oligonucleotides (Fig. 3). ThisFig. 7. Ataxin-3 is ubiquitously expressed in the central nervous system of the adult
the cerebellum and brain stem (approximate level 5.68 mm anterior to bregma) [46
the primary antibody. Mouse ataxin-3 staining is prominent in ependymal cells, as
(D), also showing the labeled cilia. (E) Low magnification of the anti-ataxin-3 lab
labeling in the Purkinje cells, also shown in higher magnification in (F). (G) L
magnification of the neuronal immunolabeling in the brain stem and (I) in the sub
cells. The black bar on the lower right corner is equivalent in (A) to 1 mm, in (G) to
ventricle; bs, brain stem; ce, cerebellum; cpu, caudate putamen; ec, ependymal ce
superior medullary velum; wm, white matter.
Fig. 8. Ataxin-3 immunoreactivity during mouse embryonic development. Sagitt
E12.5, (C) E13.5, (D) E14.5, (E) E15.5, and (F) E16.5. (F) At E16.5, the develo
ataxin-3; immunoreactivity was also found in the respiratory and digestive tracts,
oral cavity and nasopharynx and the intestinal villi, in the apical portion of entero
(sublingual and submaxillary). (G) Control for staining, without the primary a
magnification images of E16.5 embryo. The black bar in the lower right corner is
Intense ataxin-3 staining is evidenced (H) in the cochlear and (I) in the olfactory
stomach, (M) thymus (both in the medulla and in the cortex), and (N) ossification a
cells, whereas larger and more cuboidal osteoblasts appeared to exhibit no staining
plate; h, heart; i, intestine; k, kidney; l, lung; li, liver; s, stomach; sc, spinal cordresult suggests that the Mjd gene promoter is indeed
regulated by MyoD, which is a transcriptional activator of
muscle-specific genes.
Promoter activity of the 5V flanking region
To characterize the regions regulating the transcription
activity of the mouse Mjd gene, we constructed a series of
plasmids containing different lengths of the 5V flanking
region of Mjd fused to the promoterless CAT gene in
pCAT3-Basic (Promega): p-237MjdCAT, p-358MjdCAT,
p-559Mjd CAT, p-928MjdCAT, and p-1173Mjd CAT. Tran-
sient transfection assays were performed using undifferen-
tiated mouse embryonic carcinoma P19 cells. CAT activity
was normalized for transfection efficiency, with reference to
the h-galactosidase activity derived from the cotransfected
internal control plasmid. As shown in Fig. 4A, we observed
minimal activity of the promoter with the p-1173MjdCAT
construct and maximal activity with either p-237MjdCAT or
p-358MjdCAT plasmid, which presented a 94- and a 128-
fold increase over the empty pCAT3-Basic plasmid, respec-
tively. The fragments with 237 and 358 bp presented a 1.4-
fold increase over the 1173-bp segment of the 5V flanking
region of the gene. We observed a decrease in the promoter
activity for the fragments larger than 358 bp, which
suggests the existence of repressor-binding sequences in
these regions.
These results suggest that the 237 bp region of the
cloned 5V region of the Mjd gene is sufficient to direct
maximal transcription in P19 cells.
Activation of the mouse Mjd gene promoter during
differentiation of P19 cells
We next examined the behavior of the isolated promoter
sequence in terms of transcriptional activation during the
differentiation of P19 cells onto three different types of
cells: neuronal precursors, cardiac/skeletal myocytes, andmouse. (A, B) Low-magnification photomicrographs of a coronal section of
]. (A) Mouse ataxin-3 immunoreactivity and (B) control of staining, without
evidenced (C) in the cells in the fourth ventricle and at high magnification in
eling, in the different layers of the cerebellum, evidencing the cytoplasmic
ow magnification of immunoreactivity in cerebral cortex layers. (H) High
stantia nigra. The arrow points to, in (D), the labeled cilia of the ependymal
200 Am, and in (C, E, H, I) to 50 Am. I–VI, cortical layers I–VI; 4v, fourth
lls; gl, granule cell layer; ml, molecular cell layer; pk, Purkinje cells; smv,
al micrographs of mouse embryos at (A) embryonic day 11.5 (E11.5), (B)
ping cardiac, skeletal, and smooth muscle were visibly labeled for mouse
especially marking the nonkeratinizing stratified squamous epithelia of the
cytes, as well as in the adrenal glands, the pancreas, and the salivary glands
ntibody, in a sagittal section of an E13.5 mouse embryo. (H–N) High-
equivalent in (A, B) to 1 mm, in (C–G) to 2 mm, and in (H–N) to 50 Am.
epithelia. Ataxin-3 is marked in the developing (J) kidney, (K) lung, (L)
reas (the periosteum was stained, as well as the cytoplasm of osteoprogenitor
). bs, brain stem; cc, costal cartilage; ce, cerebellar primordium; cp, cortical
; sm, submaxillary gland; t, thymus.
M. do Carmo Costa et al. / Genomics 84 (2004) 361–373368endoderm cells [31,32]. To promote cellular differentiation,
P19 cells were cultured as aggregates in the presence of
medium or all-trans-retinoic acid (RA)- or dimethyl sulfox-
ide (DMSO)-supplemented medium to obtain endoderm-
like cells (untreated), neuron-like cells, or cardiac/skeletal
myocytes, respectively. A significantly higher activity of the
Mjd gene promoter was observed in cardiac and skeletal
myocytes transfected with constructs p-237MjdCAT and p-
1173MjdCAT, which presented a 244.4- and a 231.5-fold
increase in gene activity, respectively, over cells transfected
with the empty pCAT3-Basic plasmid (Fig. 4B). Endoderm-
like cells presented a 164.7- and 144.3-fold increase over
the empty-vector-transfected cells, when transfected with
constructs p-237MjdCAT and p-1173MjdCAT, respectively.
In contrast, neuron-like cells transfected with the same
constructs, p-237MjdCAT and p-1173MjdCAT, showed a
19.3- and a 23.0-fold increase, respectively, relative to cells
transfected with the empty vector (Fig. 4B). These data
indicate that at early stages of embryogenesis, the Mjd gene
is preferentially activated in endodermal (DMSO-treated
and untreated) and mesodermal (DMSO-treated) deriva-
tives, including cardiac and skeletal muscle, and relatively
less in neuronal precursors.
Mouse ataxin-3 expression in adult mouse
The expression pattern of mouse ataxin-3 was studied by
immunoblotting analysis of several tissues from adult wild-
type mice, using the anti-ataxin-3-specific antiserum that
cross-reacted with endogenous mouse ataxin-3. Tissue sam-
ples from the spinal cord, brain stem, cerebellum, cerebral
cortex, heart, skeletal muscle, testis, kidney, lung, spleen,
pancreas, liver, and stomach all presented an immunoreac-
tive band of 42 kDa that corresponded to full-length mouse
ataxin-3 and another band of approximately 160 kDa,
potentially corresponding to an SDS-resistant tetramer
(Fig. 5).
Cardiac and skeletal muscle expressed an additional and
more prominent lower molecular mass species of 38 kDa
that is also present in human counterpart tissues [9]. This
species and another of higher molecular mass were also
present in testis. Skeletal muscle presented additionally
another immunoreactive band of 40 kDa (Fig. 5). These
species could either represent different splice variants of the
mouse Mjd gene (potentially corresponding to human H2
cDNA variant described by Ichikawa and colleagues [7]) or
be the result of proteolysis. Their conservation in mouse and
human suggests that they could be of functional relevance.
To assess the regional and cellular distribution of mouse
ataxin-3, we performed immunohistochemistry studies, us-
ing the anti-ataxin-3 antiserum, in peripheral tissues and
organs and in the CNS of wild-type mice. Mouse ataxin-3
seemed to be ubiquitously distributed and to have a cyto-
plasmic localization, as evidenced in immunostained sec-
tions (Figs. 6, 7, and 8). The protein was highly expressed in
skeletal, cardiac, and smooth muscle (Figs. 6A–6D). Theflagellum of the spermatozoa stained intensely (Fig. 6K), and
Leydig cells were also reactive to the antibody (Fig. 6H).
Anti-mouse ataxin-3 immunoreactivity was found ubiq-
uitously in the CNS (Fig. 7A) and particularly localized in
the cytoplasm of both neurons and glial cells. Marked
labeling was found in the cytoplasm of neurons in the brain
stem (Fig. 7H) and in the substantia nigra (Fig. 7I). In the
substantia nigra, mouse ataxin-3 was expressed both in the
pars compacta and in the pars reticulata. In the cerebellum,
immunoreactivity was found in both the granular and the
molecular layer (Fig. 7E); in the Purkinje cells, mouse
ataxin-3 appeared to be located mainly in the cytoplasm,
as suggested by the absence of nuclear staining (Fig. 7F). As
shown in Fig. 7G, staining for mouse ataxin-3 was found in
all layers of the cerebral cortex. Myelinated fibers of the
white matter were also marked, although the staining was
less pronounced. Likewise, in fiber areas, such as the corpus
callosum and the anterior commissure, the staining was less
intense. Immunolabeling was very intense in the ependymal
cells, as observed in the lateral, third, and fourth ventricles
(Fig. 7C); the cilia of these cells were also labeled (Fig. 7D).
Expression of mouse ataxin-3 during embryonic development
To determine the pattern of expression of mouse ataxin-3
during mouse embryonic development, we performed im-
munohistochemistry using anti-ataxin-3 antiserum in sagit-
tal sections of embryos, at embryonic day (E) 11.5, E12.5,
E13.5, E14.5, E15.5, and E16.5. Mouse ataxin-3 was
continuously expressed in several tissues, including the
CNS, from the earliest age analyzed (E11.5) and exhibited
a ubiquitous distribution (Figs. 8A–8F). Ciliated epithelia,
like the olfactory (Fig. 8I) and cochlear epithelia (Fig. 8H),
were intensely stained.Discussion
In this study, we determined the entire genomic structure
of the mouse Mjd gene, characterized the functional pro-
moter activity for the 5V flanking region in transient
transfection assays, and investigated the expression of the
gene in mouse embryonic carcinoma P19 cells and its
developmental regulation in mice. Our results showed that
the mouse Mjd gene, a gene of 36 kb, has an organization
very similar to that of human MJD: both the number and the
sizes of exons and introns—11 exons and 10 introns—are
identical [7]. The Mjd gene contains a CAG repeat localized
in exon 10, as occurs in the human gene. The Mjd cDNA
has a high sequence similarity to its rat and human counter-
parts. At the amino acid level, mouse ataxin-3 revealed 94
and 82–86% identity with rat and human proteins, respec-
tively. The (CAG)n repeat in the mouse Mjd gene, as well as
in the rat gene [29], is shorter than in its human counterpart,
containing 6 triplet units compared to the range of 10–51
repeats in the normal human population [12,13]. Reduced
M. do Carmo Costa et al. / Genomics 84 (2004) 361–373 369length of polyglutamine tracts and high conservation at the
amino acid level have also been observed in mouse homo-
logues of other genes involved in human polyglutamine
disorders, such as SCA1 [33], SCA2 [34], SCA7 [35], and
HD [36,37]. This suggests that the polyglutamine stretch
may have no relevance for function in the wild-type protein
and that the expansion of repeats may be characteristic of
primates, since no natural models of expanded poly(Q) are
known in rodents.
Analysis of the 1173-bp regulating region upstream of
mouse Mjd revealed the presence of putative binding sites
for the transcription factors Sp1, USF, Max, Arnt, E47 and
MyoD, which were conserved in the 5V flanking region of
the human gene, and the presence of potential binding sites
for GATA-4, Nkx-2.5, myogenin, MEF-2, c-Myb, AP-2a,
RAR-g/RXR-h, N-Oct-3, Sox-5, GR, AP1, and MAZ.
Similar to the human MJD promoter gene, no TATA or
CCAAT boxes were found on the 5V flanking region ofMjd.
This and the presence of both constitutive and tissue-
specific transcription factor regulatory sites suggest that
the Mjd promoter is unusual, since it presents characteristics
of both housekeeping and regulated genes. Interestingly, the
results of the functional studies of this TATA-less promoter
region correlate very well with the predicted roles of these
putative transcription factor binding regions. Analysis of the
promoter activity, using a series of constructs containing
different lengths of the 5V upstream region of the Mjd gene
and CAT as a reporter gene, showed minimal activity of the
promoter for the 1173 bp fragment, whereas fragments
237 and 358 bp presented maximal activity. The pro-
gressive decrease in activity for fragments larger than 358
bp suggest the existence of repressor binding sites in these
regions. Sequence analysis of segments 237 and 358 bp
revealed the repeated presence of similar regulatory regions
on both fragments, except for the presence on the 358 bp
segment of a putative GR binding region at position 290
bp. The similarity of results for the two constructs may
relate to the absence of glucocorticoid exposure in the P19
system used in this study. The 237 bp region, containing
putative binding sites for several ubiquitous transcription
factors, such as Sp1, USF, Max, and Arnt, that are con-
served in the human promoter, seems to be sufficient to
direct maximal transcription in the P19 cells.
Having identified the minimal promoter region and
potential regulatory elements, we then studied the Mjd
promoter activity, in both RA-induced (neuronal) and
DMSO-induced (cardiac/skeletal myocytes) differentiated
P19 cells [31,32]. Cells transfected with constructs p-
237MjdCAT and p-1173MjdCAT exhibited an increase in
promoter activity of the Mjd gene when treated with
DMSO—there was a 1.5- and 1.6-fold higher activity,
respectively, relative to untreated cells. This is in agreement
with the presence on the promoter of several putative
binding regions for muscle-specific transcription factors,
including myogenin, MyoD/E47, MEF-2, GATA-4, and
Nkx-2.5. Of these, the MyoD binding site is also presentin the human promoter. We confirmed the binding of the
transcription factor MyoD to the mouse Mjd promoter by
gel shift assay. These results are confirmed by the immu-
noblotting results that showed a high expression of the Mjd
gene product—mouse ataxin-3—in cardiac and skeletal
muscle. These tissues expressed smaller isoforms of the
protein, 38 and 40 kDa in size, which are conserved in
humans [9], suggesting the functional relevance of these
isoforms. The expression of mouse-ataxin-3 in cardiac,
skeletal, and smooth muscle was also confirmed by immu-
nohistochemistry, both in adult mouse and during develop-
ment, showing a cytoplasmic localization.
Untreated preaggregated P19 cells that correspond to
endoderm-like cells [38] presented a relatively high activity
of both Mjd promoter regions (237 and 1173 bp),
suggesting that the Mjd gene could be of functional rele-
vance from the first stages of cell differentiation.
Neuron-like cells presenting morphologic and metabolic
characteristics of normal neurons were obtained by RA-
induced P19 differentiation. Interestingly, transient trans-
fection of these cells with constructs p-237MjdCAT and p-
1173MjdCAT originated an activity 8.5- and 6.3-fold
weaker, respectively, than the untreated cells. The weaker
activity of the minimal promoter (237 bp) could be
explained by the presence of two conserved putative
binding sites for Max, at positions 109 and 182 bp.
The Max and Mad genes are known to be up-regulated
during RA-induced differentiation [39], thus Max/Mad
heterodimers could bind and act as repressors of transcrip-
tion. Simultaneously, down-regulation of the activator
gene c-Myc, which is later expressed at high level (at
day 14 of differentiation) [39], could also contribute to the
observed decrease in promoter activity. Alternatively, a
decrease in transcription may occur through the AhR/Arnt
pathway, potentially acting at the conserved 105 and
178 bp binding sites. In fact, aryl hydrocarbon receptor
(AhR) has been shown to be down-regulated in RA-
treated cells [40].
Despite the presence on the p-1173MjdCAT construct of
several potential binding regions for AP-2a, N-Oct-3, and
RAR-g/RXR-h, which are activators for neuron-specific
genes, CAT activity on RA-differentiated cells transfected
with this construct was rather similar to that obtained for the
minimal promoter construct. It is possible that the potential
activation of transcription by these factors is not sufficient to
overcome the transcription repression of Mjd by the Max/
Mad pathway, at least at this stage (day 6) of RA-induced
differentiation. This does not exclude that at later stages of
embryonic development, which are not mimicked by P19
cells, these transcription factors could eventually become
activated. The presence of additional neuronal-specific
enhancers of transcription upstream of the 1173 bp pro-
moter region of Mjd also cannot be excluded and could
account for the high expression of mouse ataxin-3 observed
in the CNS during both adult and embryonic stages of the
mouse.
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ubiquitously expressed and was localized in the cytoplasm
of both neurons and glial cells. Relevant reactivity was
found in the brain stem (mainly in neurons), in the sub-
stantia nigra, and in both the granular and the molecular
layer of the cerebellum. However, a very intense expression
was also observed in other types of cells of the CNS, which
are not affected in MJD. We suggest that the pathogenic
mechanism in MJD may be independent of the function of
ataxin-3, being due not only to a prominent expression of
the mutant protein in the affected regions but also to other
factors that contribute to a selective neuronal loss.
The study of the expression pattern of mouse ataxin-3
during embryonic development revealed that it is expressed
since the early stages and confirmed the ubiquitous expres-
sion observed in adult mice.
The intense immunoreactivity of mouse ataxin-3 in epen-
dymal cells, in the flagellum of the spermatozoa, and in
ciliated olfactory and cochlear epithelia suggests that this
protein may have an important function in cell structure and/
or motility. Additionally, the presence in the promoter region
of conserved binding sites for muscle-specific transcription
factors, and the high activity of the Mjd promoter in DMSO-
treated cells, in conjunction with the very intense expression
of mouse ataxin-3 in cardiac, skeletal, and smooth muscle,
suggests that the function of Mjd may be relevant in these
tissues. These results can also be related to the structural
modeling of ataxin-3, which has a distant homology to
adaptins [28]. Adaptins are functionally related to and
involved in the cytoskeleton machinery, vesicular traffick-
ing, and clathrin-dependent endo- and exocytosis [28].
Further studies are necessary to determine whether mouse
ataxin-3 may be a cytoskeleton-associated protein that could
be important for motility and for cellular transport.
In summary, our studies indicate that MJD is highly
conserved between species, within coding and 5V regulatory
regions, and its regulated expression during development
suggests that ataxin-3 may have an important biological
function. Given this conservation, the study of mouse Mjd
may provide fundamental insights into the function of human
ataxin-3.Materials and methods
Computational methods
We applied the BLAST program [41] to search for the
homologue cDNA sequence in mouse under Accession No.
AK008675. All protein sequences were taken from the
TrEMBL database. The accession numbers of human variants
ataxin-3-v1, ataxin-3-v2/v3 as denoted in [28], and ataxin-3-
v4 corresponding to H2 in [7]; rat ataxin-3;and mouse ataxin-
3 are Q96TC4, Q96TC3, Q96TC3, BAB18798, O35815, and
Q9CVD2, respectively. Multiple sequence alignment was
constructed by means of CLUSTALW [42]. Comparison ofMJD sequence to the homologous 5V upstream region in
mouse Mjd was performed to uncover evolutionarily con-
served regions using TRES/TRANSFACwith a score of 95%
[43]. Conserved regions in Mjd were then scanned for the
presence of potential transcription factor binding regions
using TESS [44].
Cloning of the full-length Mjd and MyoD cDNAs by RT-PCR
Total RNAwas isolated from adult C57Bl/6 mouse brain
and skeletal muscle, using Trizol reagent (Gibco BRL). Five
micrograms of total RNA was used to perform reverse
transcription using the SuperScript First-Strand Synthesis
System for RT-PCR (Gibco BRL) with an oligo(dT) primer.
To amplify the Mjd cDNA, PCR was carried out using the
Expand High Fidelity System (Roche) with primers
mmMJD1 and mmMJD2 (see below) using mouse brain
total RNA as template. To amplify the MyoD cDNA, PCR
was carried out using the same system with primers MyoD1
and MyoD2 (see below) using mouse skeletal muscle total
RNA as template. The PCR conditions consisted of 1 cycle
of 2 min at 94jC, followed by 32 cycles of 1 min at 94jC, 1
min at 62jC, and 1 min at 72jC, and ending with 5 min at
72jC. The PCR products corresponding to Mjd and to
MyoD cDNAs were purified using GFX PCR DNA and
the Gel Band Purification Kit (Amersham Pharmacia Bio-
tech) and cloned into the pGEM-T Easy vector (Promega)
(pMjd1) and into the pDONR207 vector, respectively,
using the Gateway system (Invitrogen Life Technologies)
(pDON207MyoD).
PCR
The primers used for RT-PCR were mmMJD1 (5V-
GAGGGGCTGCTCCGCGCCGGGGCCGT), mmMJD2
(5V-TCTGCTTTCAAGTTGTCTTTAGCAG), MyoD1
(5V-GGGGACAAGTTTGTACAAAAAAGCAGGCTA-
TATGGAGCTTCTATCGCCGCCACTCCG), and MyoD2
(5V-GGGGACCACTTTGTCCAAGAAAGCTGGGTCT-
CAAAGCACCTGATAAATCGCATTG). The probe used
for screening the BAC library was amplified by PCR, using
the Mjd cDNA (pMjd1) as template, with primers mmMJD1
and mmMJD3 (5V-GTAAACCAGTGTTCTTTA-
TAATTGCA), and performed with the same cyclic param-
eters used for RT-PCR. PCRs for the construction of CAT
reporter plasmids were all performed using the Expand High
Fidelity System (Roche) and performed under the following
conditions: 1 cycle of 5 min at 95jC, followed by 35 cycles
of 1 min at 95jC, 1 min at 55jC, 1 min at 72jC, and ending
with 5 min at 72jC. For the insertion of the restriction
enzyme sites we used the reverse primer PMjd-1BglIIR (5V-
GCACAGATCTGTTTATTTGTCTGGAG) in conjunction
with one of the forward primers: PMjd-237KpnIF (5V-
CGAGGGTACCACAGCAGGCGGCGCC), PMjd-
358KpnIF (5V-GCACGGTACCAGAAGGTGGAGATGG),
PMjd-559KpnIF (5V-GGCTGGTACCGTATAATATTA-
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GGGTCCTCCTATGTAAC), or PMjd-1173KpnIF (5V-
GGCTGGTACCCCAGTCCCTCATCAAAGT).
Isolation of a genomic BAC clone
The genomic BAC clone was obtained from Incyte
Genomics, Inc. A BAC Mouse II library was screened by
direct hybridization, using a probe of 400 bp, constructed by
PCR, using primers mmMJD1 and mmMJD3. These pri-
mers were designed on the basis of the cloned Mjd cDNA
sequence. The positive BAC clone was grown overnight, at
37jC, in 2XYT medium containing the appropriate antibi-
otic (25 Ag/ml chloramphenicol). BAC DNA was isolated
using the Qiagen Large-Construct Kit (Qiagen).
Cell culture and differentiation
The P19 clone was obtained from the American Type
Collection. Cells were cultured (plating 106 cells in 75-cm3
tissue culture flasks, every 2 days) in Dulbecco’s modified
Eagle’s medium (DMEM), supplemented with 10% fetal
bovine serum (FBS), in a 5% CO2 humidified chamber at
37jC. To promote cellular differentiation, cells were cul-
tured as aggregates, in bacterial petri dishes, in medium
supplemented with 1 AM RA (Sigma) for neuronal differ-
entiation or with 1% DMSO for cardiac/skeletal myocyte
differentiation. Cells (1  105/ml culture) were plated into
bacterial petri dishes (day 0) and incubated with medium
(no treatment) or with RA- or DMSO-supplemented medi-
um, for 2 days. After 2 days, floating aggregates were
collected and washed with medium and replated into bac-
terial petri dishes for 1 additional day. At day 3, the
aggregates were harvested; dissociated by treatment with
0.25% trypsin, 1 mM EDTA (Gibco BRL); and then plated
in DMEM, 10% FBS in 60-mm diameter tissue-culture-
grade dishes. At day 4, cells were transfected with con-
structs p-237MjdCAT and p-1173MjdCAT. Cell viability
was assessed by trypan blue exclusion.
Construction of CAT reporter and MyoD-His tag expression
plasmids
To obtain different lengths of the 5V flanking region of
Mjd, PCRs were performed using the BAC clone 27521 as
the template. We used the primer PMjd-1BglIIR to insert the
3V restriction enzyme site for BglII (at the position 1 bp)
into all fragments, in conjunction with one of the primers
PMjd-237KpnIF, PMjd-358KpnIF, PMjd-559KpnIF, PMjd-
928KpnIF, or PMjd-1173KpnIF to insert the 5V restriction
enzyme site for KpnI, at the respective lengths of the 5V
region 237, 358, 559, 928, or 1173 bp. These PCR
products were digested with BglII and KpnI and subcloned
into BglII—KpnI-digested pCAT3-Basic vector (Promega).
The resultant constructs were p-237MjdCAT, p-358MjdCAT,
p-559MjdCAT, p-928MjdCAT, and p-1173MjdCAT. Therecombinant mouse MyoD-His tag protein expression plas-
mid (pDEST17MyoD) was obtained by recombination of the
pDONR207MyoD with the pDEST17 vector using the
Gateway system (Invitrogen Life Technologies). All con-
structs were confirmed by automatic sequencing.
Expression and purification of recombinant MyoD-His tag
protein
The pDEST17MyoD construct was transformed in
Escherichia coli BL21SI bacteria. Culture was grown to
OD600 of 0.5 L of LBON medium plus ampicillin (100 Ag/
ml). The expression was induced by the addition of NaCl to
a final concentration of 0.3 M and culture was grown for 30
min. Cells were harvested, resuspended in 15 ml of phos-
phate buffer 1, imidazole 10 mM, lysozyme 66 Ag/ml,
Triton X-100 0.1%, Complete EDTA-free protease inhibitor
cocktail tablet (Roche) and incubated on ice for 1 h. The
lysate was sonicated on ice eight times for 30 s each time
and then centrifuged for 15 min at 12,000 rpm at 4jC. The
supernatant was collected and the recombinant protein was
purified using the HisTrap Kit (Amersham Pharmacia Bio-
tech) using the manufacturer’s conditions.
Electrophoretic mobility-shift assay
The 928 bp fragment of the Mjd gene promoter,
generated by KpnI/BglII restriction of the p-928MjdCAT,
was used for EMSA. For the competition assay, single-
stranded sense and antisense MyoD oligonucleotides were
synthesized based on both the sequence in the 5V region of
the Mjd gene and the binding matrix for MyoD with
Accession No. M00184 (TRANSFAC database). The oli-
gonucleotides MyoD-sense (5V-AGCAGCTGTC) and
MyoD-antisense (5V-GACAGCTGCT) were annealed by
incubation at 30jC for 1 min and by slow cooling to room
temperature. DNA–protein binding assays were performed
at room temperature for 30 min, always using the same
amount of DNA (300 ng of the 928 bp fragment) and
different quantities of recombinant mouse MyoD protein in
a final volume of 40 Al of TE. In the competition assay, the
double-stranded oligonucleotides (2 or 4 Ag) were incubated
with the recombinant protein for 30 min before the incuba-
tion with the DNA. The mixtures were loaded in a 1.5%
agarose gel and electrophoresed at room temperature.
Cell transfection and CAT assay
To analyze activities of the CAT reporter plasmids in
undifferentiated, untreated (day 3), RA-treated (day 3), and
DMSO-treated (day 3) P19 cells, these were seeded at 2 
105, 7.5  105, 7.5  105, and 3  106 cells, respectively,
per 60-mm-diameter tissue-culture-grade dishes in DMEM,
10% FBS 24 h prior to transfection. Transient transfection
was carried out in serum-free medium (Opti-MEM; Life
Technologies), using 10 Al of Lipofectamine2000 Reagent
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struct and 0.5 Ag of pSV-h-galactosidase control vector
(Promega). After transfection for 5 h, medium was replaced
with DMEM, 10% FBS. Cells were harvested 48 h after
transfection and washed three times with phosphate-buff-
ered saline (PBS), and then cell extracts were prepared in
1 reporter lysis buffer (Roche). Cell extracts were assayed
for CAT activity, using the CAT ELISA kit (Roche).
Measurements were performed in duplicate, averaged, and
then normalized to the h-galactosidase activity, to correct
for transfection efficiency, and to the total protein amount.
h-Galactosidase activity was measured using the h-Galac-
tosidase Enzyme Activity System (Promega), and the total
protein amount was assessed using the Lowry Protein assay
kit (Sigma).
Immunoblotting
Proteins were extracted from different tissues of adult
C57Bl/6 mice, using standard methods [45]. Total protein
quantification was assessed using the Lowry Protein assay
kit (Sigma). Proteins of spinal cord, brain stem, cerebellum,
cerebral cortex, heart, skeletal muscle, testis, kidney, lung,
spleen, pancreas, liver, and stomach tissues (30 Ag) were
resolved on a 10% SDS–polyacrylamide gel and transferred
onto nitrocellulose membrane (Amersham Biotechnologies).
The anti-human ataxin-3-specific antiserum (kindly provid-
ed by Henry Paulson) was used (1:2000). For detection of
the immunocomplexes formed, the secondary antibody
peroxidase-conjugated goat anti-rabbit IgG (Stressgen)
(1:4000) or goat anti-mouse IgG (Jackson Immunoresearch
Laboratories) (1:1000) was used. Staining intensity was
developed with the chemiluminescence system (Roche).
Immunohistochemistry
Adult male C57Bl/6 mice were perfused transcardially,
under anesthesia, with fixative solution (4% paraformalde-
hyde, in 0.1 M phosphate buffer, pH 7.4), for 10 min. The
encephalon and peripheral tissues (skeletal muscle, cardiac
muscle, pancreas, spleen, liver, and testis) were postfixed
for 2 h in the same fixative. Mouse embryos were isolated
from pregnant C57Bl/6 female mice, at E11.5, E12.5,
E13.5, E14.5, E15.5, and E16.5. The day of plug detection
was considered to be E0.5 (embryonic day 0.5). Embryos
were washed with ice-cold PBS and fixed in 10% buffered
formalin, for at least 24 h, at 4jC. After fixation, the
samples (adult tissues and organs and embryos) were
paraffin embedded. Nominal 5-mm tissue sections were
cut and mounted onto positively charged slides (X-Tra
Slides), deparaffinized on xylene, and rehydrated by pas-
sages through graded ethanol series. In formalin-fixed
material, heating was performed to allow antigen recovery.
Nonspecific binding was blocked with normal goat serum
(Vectastain Elite ABC kit; Vector Laboratories). Sections
were incubated overnight in primary anti-ataxin-3 antiserumdiluted (1:2000) in PBS. Antibody labeling was visualized
using the secondary anti-rabbit antibody by the avidin–
biotin conjugation method (Vectastain Elite ABC kit; Vector
Laboratories) and 3,3-diaminobenzidine (Vector Laborato-
ries). Sections were counterstained with hematoxylin. De-
hydration of sections was assessed through graded ethanols
and xylene. Slides were mounted with Histomount. Positive
controls were processed in parallel. Sections were analyzed
using an Olympus BX-50 microscope, equipped with a
Camedia C-2000Z Olympus digital camera. High-quality
(1600  1200 pixel) images were captured to a PC equipped
with the Olympus DP-Soft 3.0 software. Brain sections were
referenced to [46].Acknowledgments
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